No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: A population-based study of 1207 cases

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Xu, Bei ^a   Liu, Peng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGE; AGED; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHILD; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; TREND STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; POPULATION SURVEILLANCE; PROGNOSIS; SEER PROGRAM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898656684     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092585     Document Type: Article

References (32)

1. Iannitto E, Ferreri AJ, Minardi V, Tripodo C, Kreipe HH (2008) Angioimmunoblastic T-cell lymphoma. Crit Rev Oncol Hematol 68:264-271.
2. de Leval L, Gisselbrecht C, Gaulard P (2010) Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 148:673-689.
3. Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, et al. (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 13:140-149. (Pubitemid 34436738)
4. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, et al. (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316-2323. (Pubitemid 47523150)
5. Delmer A, Fitoussi O, Gaulard P, Laurent G, Bordessoule D, et al. (2009) A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial. Journal of Clinical Oncolology (ASCO Meeting Abstracts), 27 (Suppl. 15):8554.
6. Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, et al. (2012) Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica 97:1594-1602.
7. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, et al. (2009) Phase II multiinstitutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27:5410-5417.
8. O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, et al. (2007) Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 139:425-428. (Pubitemid 47512170)
9. Schetelig J, Fetscher S, Reichle A, Berdel WE, Beguin Y, et al. (2003) Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 88:1272-1278. (Pubitemid 37456382)
10. Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, et al. (2008) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:218-224.
11. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, et al. (2004) Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172-2176. (Pubitemid 41095152)
12. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, et al. (2008) Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 26:2264-2271.
13. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, et al. (2009) Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 27:3951-3958.
14. Siegert W, Nerl C, Agthe A, Engelhard M, Brittinger G, et al. (1995) Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 6:659-664.
15. Park BB, Ryoo BY, Lee JH, Kwon HC, Yang SH, et al. (2007) Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 48:716-722. (Pubitemid 46605543)
16. Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, et al. (2008) Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 111:4463-4470.
17. Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, et al. (2012) Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood 119:2837-2843.
18. Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, et al. (2013) Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 31:240-246.
19. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2012 Sub (1973-2010 varying) - Linked To County Attributes - Total U.S., 1969-2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission.
20. Percy C, Van Holten V, Muir C (1990) International Classification of Diseases for Oncology. 2nd ed. Geneva:World Health Organization.
21. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, et al. (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107:265-276. (Pubitemid 43053551)
22. Pangalis GA, Moran EM, Nathwani BN, Zelman RJ, Kim H, et al. (1983) Angioimmunoblastic lymphadenopathy. Long-term follow-up study. Cancer 52:318-321. (Pubitemid 13063175)
23. Aozasa K, Ohsawa M, Fujita MQ, Kanayama Y, Tominaga N, et al. (1989) Angioimmunoblastic lymphadenopathy. Review of 44 patients with emphasis on prognostic behavior. Cancer 63:1625-1629. (Pubitemid 19093295)
24. Ch'ang HJ, Su IJ, Chen CL, Chiang IP, Chen YC, et al. (1997) Angioimmunoblastic lymphadenopathy with dysproteinemia - lack of a prognostic value of clear cell morphology. Oncology 54:193-198.
25. Archimbaud E, Coiffier B, Bryon PA, Vasselon C, Brizard CP, et al. (1987) Prognostic factors in angioimmunoblastic lymphadenopathy. Cancer 59:208-212. (Pubitemid 17232876)
26. Schlegelberger B, Zwingers T, Hohenadel K, Henne-Bruns D, Schmitz N, et al. (1996) Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type. J Clin Oncol 14:593-599. (Pubitemid 26051026)
27. Lin HN, Liu CY, Hong YC, Pai JT, Yang CF, et al. (2010) Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. Leuk Lymphoma 51:2208-2214.
28. Lee SS, Rüdiger T, Odenwald T, Roth S, Starostik P, et al. (2003) Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer 103:12-20. (Pubitemid 35424200)
29. Hershman DL, Wright JD (2012) Comparative effectiveness research in oncology methodology: observational data. J Clin Oncol 30:4215-4222.
30. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, et al. (2013) A targeted mutational landscape of angioimmunoblastic T cell lymphoma. Blood. Dec 17. [Epub ahead of print] PMID: 24345752
31. Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, et al. (2004) Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev 13:138-143. (Pubitemid 38116631)
32. Yu JB, Gross CP, Wilson LD, Smith BD. (2009) NCI SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park) 23:288-295.